CLINICAL EFFECTIVENESS OF REGDANVIMAB IN THE TREATMENT OF PATIENTS WITH COVID-19: A SYSTEMATIC REVIEW AND META-ANALYSIS
Background & Aims:
Regdanumab is a monoclonal antibody that is widely used to treat the patients with COVID-19. The aim of this study was to investigate the clinical effectiveness of Regdanumab in the patients with COVID-19.
Materials & Methods:
A systematic review of the most important major databases including; PubMed, Cochrane Library, Scopus and Web of Science were conducted up to August 2022. Also, a manual search was performed in the sources of primary review and key studies. No restrictions were considered for the language and year of publication of the studies. Evaluation of the quality of studies was performed using the Newcastle checklist. Efficacy outcomes included reduction in mortality, length of hospital stay, disease progression, and need for oxygen therapy. Meta-analysis was performed using Comprehensive Meta-Analysis version 3 software.
Out of 208 articles, seven studies met the inclusion criteria. The results of the meta-analysis showed that the risk ratio (RR) in the Regdanumab group was 0.23 (CI95% 0.05 - 1.02), for the duration of hospitalization was -1.15 (CI95% -0.49 - 1.80), and the need for oxygen therapy was 0.43 (CI95% 0.34-0.56). However, no significant effect was observed for the outcomes of mortality rate, mechanical ventilation and clinical improvement (P˃0.05).
The results of the meta-analysis showed that Regdanumab reduces mortality and length of hospitalization in the patients with COVID-19; although it had no effect on reducing the need for mechanical ventilation and clinical improvement in patients.
- حق عضویت دریافتی صرف حمایت از نشریات عضو و نگهداری، تکمیل و توسعه مگیران میشود.
- پرداخت حق اشتراک و دانلود مقالات اجازه بازنشر آن در سایر رسانههای چاپی و دیجیتال را به کاربر نمیدهد.